Five articles suggested by Yüksel Ürün

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.

He suggested following few must-read papers on X:

1. “Cancer cells use “3 Cs” to evade the immune system:
-Camouflage: Hiding from immune detection.
-Coercion: Disrupting immune function.
-Cytoprotection: Shielding from immune attacks.
Blocking these mechanisms enhances immunotherapy and restores anticancer immune surveillance.”

The hallmarks of cancer immune evasion

Authors: Claudia Galassi, Timothy A. Chan, Ilio Vitale and Lorenzo Galluzzi.

2.  “APCCC 2024 focuses on key challenges in advanced Prostate Cancer management. Highlights include new consensus! Congratulations Silke Gillessen, Aurelius Omlin for extraordinary efforts!

Happy to take a part alongside the great panel members!”

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Authors: Silke Gillessen, et al.

3. “Improved outcomes in early breast cancer! For patients diagnosed since 2000, distant recurrence rates dropped by 25% (ER+) and 19% (ER-).

Long-term risks persist, but progress is clear.”

Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials

Authors: Early Breast Cancer Trialists’ Collaborative Group.

4. “Whole-pelvis radiation therapy (WP-RT) improves cancer-specific and overall survival compared to bladder-only RT in muscle-invasive bladder cancer.”

Benefit of Whole-Pelvis Radiation for Patients With Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis

Authors: Gautier Marcq, Ronald Kool, Alice Dragomir, Girish S. Kulkarni, Rodney H. Breau, Michael Kim, Ionut Busca, Hamidreza Abdi, Mark Dawidek, Michael Uy, Gagan Fervaha, Nimira Alimohamed, Jonathan Izawa, Claudio Jeldres,  Ricardo Rendon, Bobby Shayegan, Robert Siemens, Peter C. Black, Fabio L. Cury and Wassim Kassouf.

5. “A new CRISPR-based mouse model for VHL-deficient clear cell kidney cancer shows promise.

Though not fully HIF2-dependent, challenges remain in mimicking human tumor behavior.”

Toward a CRISPR-based mouse model of Vhl-deficient clear cell kidney cancer: Initial experience and lessons learned

Authors: Laura A. Stransky, et al.

For more articles suggested by Yuksel Urun, visit OncoDaily.